Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients
© 2023. The Author(s)..
Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
GeroScience - 46(2024), 2 vom: 01. Feb., Seite 1561-1574 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tóth, Emese [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 02.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11357-023-00887-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361541007 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361541007 | ||
| 003 | DE-627 | ||
| 005 | 20240202232008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11357-023-00887-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM361541007 | ||
| 035 | |a (NLM)37656328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tóth, Emese |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoantibody | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a IgM | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Multi-producer | |
| 650 | 4 | |a Post-COVID | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Severe COVID-19 | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Fagyas, Miklós |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Béla |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Siket, Ivetta Mányiné |e verfasserin |4 aut | |
| 700 | 1 | |a Szőke, Blanka |e verfasserin |4 aut | |
| 700 | 1 | |a Mártha, Lilla |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdi, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Erdősi, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Pólik, Zsófia |e verfasserin |4 aut | |
| 700 | 1 | |a Kappelmayer, János |e verfasserin |4 aut | |
| 700 | 1 | |a Papp, Zoltán |e verfasserin |4 aut | |
| 700 | 1 | |a Borbély, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Szabó, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Balla, József |e verfasserin |4 aut | |
| 700 | 1 | |a Balla, György |e verfasserin |4 aut | |
| 700 | 1 | |a Bácsi, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Szekanecz, Zoltán |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Tóth, Attila |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t GeroScience |d 2017 |g 46(2024), 2 vom: 01. Feb., Seite 1561-1574 |w (DE-627)NLM26925417X |x 2509-2723 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:1561-1574 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11357-023-00887-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 2 |b 01 |c 02 |h 1561-1574 | ||